KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Enterprise Value (2020 - 2025)

Historic Enterprise Value for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to -$663.0 million.

  • Recursion Pharmaceuticals' Enterprise Value fell 5446.62% to -$663.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$663.0 million, marking a year-over-year decrease of 5446.62%. This contributed to the annual value of -$597.4 million for FY2024, which is 5131.74% down from last year.
  • Per Recursion Pharmaceuticals' latest filing, its Enterprise Value stood at -$663.0 million for Q3 2025, which was down 5446.62% from -$528.2 million recorded in Q2 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' Enterprise Value peaked at -$219.1 million during Q1 2021, and registered a low of -$663.0 million during Q3 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' median Enterprise Value value was -$503.5 million (recorded in 2025), while the average stood at -$486.2 million.
  • In the last 5 years, Recursion Pharmaceuticals' Enterprise Value crashed by 16975.08% in 2022 and then soared by 3687.06% in 2024.
  • Recursion Pharmaceuticals' Enterprise Value (Quarter) stood at -$516.6 million in 2021, then dropped by 6.7% to -$551.2 million in 2022, then grew by 28.37% to -$394.8 million in 2023, then tumbled by 51.32% to -$597.4 million in 2024, then fell by 10.98% to -$663.0 million in 2025.
  • Its last three reported values are -$663.0 million in Q3 2025, -$528.2 million for Q2 2025, and -$503.5 million during Q1 2025.